Associations of antinuclear antibodies (ANA) with continuous variables. Differences for which 95% CI do not overlap zero, and are therefore significant (p < 0.05), are shown in bold type. For t tests and multiple regression analysis, the difference between the mean for patients with each ANA and the mean for all patients without that ANA is shown. For Mann-Whitney U tests, the difference between median values for patients with each ANA and for all patients without that ANA is given.
| Criteria | Difference Between ACA (n = 91) and not ACA (95% CI) | Difference Between Anti-topo I (n = 16) and Not Anti-topo I (95% CI) | Difference Between Anti-RNP (n = 15) and not Anti-RNP (95% CI) | Difference Between Anti-Th/To (n = 14) and Not Anti-Th/To (95% CI) |
|---|---|---|---|---|
| Age at diagnosis of lcSSc, yrs | 4.6 (1.0 to 8.2) | −2.5 (−8.9 to 3.9) | −8.6 (−15.1 to −2.0) | −4.6 (−11.0 to 1.8) |
| Skin score* | −2 (−3 to 0) | 2 (0 to 5) | 0 (−2 to 2) | 0 (−3 to 1) |
| Expected FVC, % | 11.6 (6.7 to 16.4) | −9.1 (−23 to 5.0) | −9.9 (−19.2 to −0.6) | 1.1 (−6.4 to 14.6) |
| Expected DLCO, % | −0.18 (−5.1 to 4.7) | −6.4 (−18 to 5.6) | 2.4 (−6.8 to 11.7) | −2.1 (−11.4 to 7.2) |
| Expected KCO*, % | −6 (−12 to 0) | 6 (−5 to 15) | 8 (−3 to 19) | −2 (−14 to 11) |
| Creatinine clearance** | −12.4 (−21.5 to −3.3) | 12.7 (−3.0 to 28.3) | −0.9 (−17.5 to 15.7) | 0.8 (−16.0 to 17.6) |